Skip to main content

Table 3 The effect of accelerated RRT initiation on outcomes, by quartiles of baseline fluid balance

From: Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial

 

Quartile 1

Quartile 2

Quartile 3

Quartile 4

p value for trend

Acc n = 347

Std n = 338

RR (95% CI)

Acc n = 360

Std n = 325

RR (95% CI)

Acc n = 335

Std n = 349

RR (95% CI)

Acc n = 336

Std n = 348

RR (95% CI)

Outcome

90-day all-cause mortality, n (%)

146 (42.1)

128 (37.9)

1.11 (0.92 to 1.34)

166 (46.1)

146 (44.9)

1.03 (0.87 to 1.21)

157 (46.9)

152 (43.6)

1.08 (0.91 to 1.27)

140 (41.7)

167 (48.0)

0.87 (0.73 to 1.03)

0.08

RRT dependence at 90 days, n (%)

24 (12.0)

18 (8.6)

1.40 (0.79 to 2.54)

19 (9.8)

9 (5.1)

1.93 (0.92 to 4.37)

17 (9.6)

11 (5.7)

1.68 (0.82 to 3.59)

19 (9.9)

10 (5.6)

1.78 (0.87 to 3.89)

0.61

Death or RRT dependence at 90 days, n (%)

170 (49.0)

146 (43.2)

1.13 (0.96 to 1.34)

185 (51.4)

155 (47.7)

1.08 (0.93 to 1.26)

174 (51.9)

163 (46.7)

1.11 (0.96 to 1.30)

159 (47.3)

177 (50.9)

0.93 (0.80 to 1.08)

0.12

ICU mortality, n (%)

98 (28.2)

90 (26.6)

1.06 (0.83 to 1.36)

110 (30.6)

106 (32.6)

0.94 (0.75 to 1.17)

115 (34.3)

115 (33.0)

1.04 (0.84 to 1.29)

113 (33.7)

128 (36.8)

0.92 (0.75 to 1.12)

0.52

28-day mortality, n (%)

122 (35.2)

108 (32.0)

1.10 (0.89 to 1.36)

134 (37.2)

120 (36.9)

1.01 (0.83 to 1.23)

137 (40.9)

124 (35.5)

1.15 (0.95 to 1.40)

116 (34.5)

134 (38.5)

0.90 (0.73 to 1.09)

0.31

Hospital mortality, n (%)

121 (35.0)

106 (31.5)

1.11 (0.90 to 1.37)

140 (39.0)

125 (38.5)

1.01 (0.84 to 1.23)

137 (41.1)

128 (36.8)

1.12 (0.93 to 1.35)

125 (37.5)

151 (43.4)

0.87 (0.72 to 1.04)

0.14

   

MD

  

MD

  

MD

  

MD

 

ICU LOS, days (IQR)

7 (4, 13)

7 (4, 14)

 − 0.1 (− 1.70 to 1.57)

8 (4,14)

8 (4,17)

 − 1.6 (− 3.46 to 0.31)

8 (4,14)

10 (5, 17)

 − 2.0 (− 3.84 to − 0.2)

10 (5, 18)

11 (6, 21)

 − 1.8 (− 4.02 to 0.44)

0.19

Hospital LOS, days (IQR)

16 (8, 34)

18 (8, 32)

1.2 (− 2.72 to 5.03)

19 (8,36)

18 (7,36)

 − 0.7 (− 4.35 to 2.97)

18 (8,35)

21 (11, 37)

 − 2.4 (− 6.20 to 1.38)

23 (9, 43)

23 (9, 48)

 − 1.0 (− 5.1 to 3.14)

0.35

Ventilator-free days@D28, days (IQR)

17 (0, 26)

19 (0, 26)

 − 0.6 (− 2.43 to 1.21)

13 (0, 24)

10 (0, 24)

0.9 (− 0.87 to 2.63)

10 (0,24)

13 (0, 23)

 − 0.1 (− 1.86 to 1.61)

8 (0, 21)

2 (0, 20)

1.4 (− 0.23 to 2.97)

0.21

Vasoactive-free days@D28, days IIQR)

22 (0, 26)

23 (0, 26)

 − 0.5 (− 2.33 to 1.31)

20 (0, 26)

18 (0, 25)

0.9 (− 0.90 to 2.67)

20 (0,25)

19 (0, 25)

 − 0.7 (− 2.51 to 1.09)

20 (0, 25)

18 (0, 25)

1.1 (− 0.63 to 2.91)

0.41

ICU-free days@D28, days (IQR)

12 (0, 22)

14 (0, 22)

 − 0.5 (− 2.08 to 1.09)

8 (0, 20)

1 (0, 20)

0.9 (− 0.60 to 2.46)

1 (0,20)

5 (0, 19)

 − 0.1 (− 1.64 to 1.42)

4 (0, 19)

0 (0, 16)

1.9 (0.43 to 3.28)

0.08

Hospitalization-free days@D90, days (IQR)

16 (0, 68)

39 (0, 69)

 − 3.6 (− 8.71 to 1.58)

6 (0, 65)

8 (0, 67)

 − 0.2 (− 5.13 to 4.68)

0 (0,62)

10 (0, 63)

 − 1.3 (− 6.16 to 3.47)

10 (0, 59)

0 (0, 54)

4.6 (− 0.01 to 9.20)

0.04

  1. Acc accelerated, Std standard, ACM all-cause mortality, RRT renal replacement therapy, LOS length of stay, IQR interquartile range, MD mean difference between (accelerated-standard)